GT Biopharma Inc (GTBP)

$2.80 -0.02 (-0.71%)
Market Cap 7.29M
Revenue (ttm) 0.00
Net Income (ttm) -13.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 38,500
Avg Vol 56,494
Day's Range N/A - N/A
Shares Out 2.59M
Stochastic %K 36%
Beta 1.37
Analysts Strong Sell
Price Target $11.00

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 919 4040
Address:
315 Montgomery Street, 10th Floor, San Francisco, United States
BiopharmaWatch_com
BiopharmaWatch_com Jun. 16 at 6:14 PM
🚀 Hot IND Filings Ahead! 🚀 Watch these biotech plays gearing up for IND filings in H1 & Mid-2025: • $GTBP GTB-5550 (solid tumors) – PoA 10% • $ALXO ALX2004 (EGFR ADC) – PoA 25% • $ERAS ERAS-0015 (NRAS melanoma) – PoA 12% • $MOLN MP0712 (DLL3 target) – PoA 12% • $SLDB SGT-501 (gene therapy for CPVT) – PoA 30% Early-stage catalysts worth tracking for potential moves! Get full details & real-time updates at biopharmawatch.com #Biotech #INDFilings #Catalysts #BiotechInvesting
0 · Reply
QuiverQuant
QuiverQuant Jun. 13 at 2:57 PM
GT Biopharma, Inc. Appoints David C. Mun-Gavin to Board of Directors Read more on $GTBP: https://www.quiverquant.com/news/GT+Biopharma%2C+Inc.+Appoints+David+C.+Mun-Gavin+to+Board+of+Directors
0 · Reply
Beastmade
Beastmade Jun. 11 at 3:48 PM
$GTBP What in the MK ultra am I making money on?
1 · Reply
Beastmade
Beastmade Jun. 11 at 12:04 AM
$GTBP Shoutout to truth social for putting me on this.
0 · Reply
PhishTourFunds
PhishTourFunds Jun. 9 at 9:24 PM
$GTBP Steady as she goes
1 · Reply
kshonstocks
kshonstocks Jun. 9 at 5:33 PM
$GTBP hitting scans, higher highs
0 · Reply
nassermahashir
nassermahashir May. 28 at 10:20 AM
$GTBP wild runner will be here 🤑🤑🤑
0 · Reply
PhishTourFunds
PhishTourFunds May. 25 at 3:36 AM
$GTBP Just filling the wick on the 3 month chart to $3.12
0 · Reply
PenkeTrading
PenkeTrading May. 22 at 2:49 AM
I found you a MACD Bearish Reversal Divergence on the daily chart of GT Biopharma Inc. $GTBP #BearishReversalDivergence #NASDAQ
0 · Reply
woolpourpis69
woolpourpis69 May. 21 at 11:31 PM
$GTBP
0 · Reply
Latest News on GTBP
GT Biopharma Appoints New Member to its Board of Directors

Jun 13, 2025, 9:00 AM EDT - 4 days ago

GT Biopharma Appoints New Member to its Board of Directors

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 19, 2025, 9:00 AM EDT - 4 weeks ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

GT Biopharma Announces Exercise of Warrants

Feb 25, 2025, 2:00 PM EST - 4 months ago

GT Biopharma Announces Exercise of Warrants

GT Biopharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:00 PM EST - 7 months ago

GT Biopharma Reports Third Quarter 2024 Financial Results

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:15 AM EDT - 9 months ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Sep 24, 2024, 9:15 AM EDT - 9 months ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

What made GT Biopharma stock more than double on Monday?

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 26, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Feb 1, 2024, 11:00 AM EST - 1 year ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 6, 2023, 9:30 AM EST - 1 year ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Dec 4, 2023, 9:30 AM EST - 1 year ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 6, 2023, 9:30 AM EST - 1 year ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GT Biopharma Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 9:00 AM EDT - 1 year ago

GT Biopharma Reports Third Quarter 2023 Financial Results

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

GT Biopharma Names Charles J. Casamento to the Board of Directors

May 4, 2023, 9:05 AM EDT - 2 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Mar 30, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 24, 2023, 9:00 AM EST - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Feb 2, 2023, 9:46 AM EST - 2 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 30, 2022, 8:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 14, 2022, 7:30 AM EST - 2 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Dec 12, 2022, 7:30 AM EST - 2 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 3:15 PM EST - 2 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 2 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 31, 2022, 5:15 PM EDT - 2 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 25, 2022, 2:44 PM EDT - 2 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 6, 2022, 8:18 AM EDT - 2 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Oct 4, 2022, 4:10 PM EDT - 2 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Jun 10, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 16, 2022, 8:01 AM EDT - 3 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

May 12, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Apr 11, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 28, 2022, 4:15 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Mar 21, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

Mar 9, 2022, 4:24 PM EST - 3 years ago

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

Mar 3, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

Feb 24, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

Feb 18, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

Jan 20, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2022, 4:30 PM EST - 3 years ago

GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

Dec 8, 2021, 7:30 AM EST - 3 years ago

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021

Nov 30, 2021, 7:30 AM EST - 3 years ago

GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021

BiopharmaWatch_com
BiopharmaWatch_com Jun. 16 at 6:14 PM
🚀 Hot IND Filings Ahead! 🚀 Watch these biotech plays gearing up for IND filings in H1 & Mid-2025: • $GTBP GTB-5550 (solid tumors) – PoA 10% • $ALXO ALX2004 (EGFR ADC) – PoA 25% • $ERAS ERAS-0015 (NRAS melanoma) – PoA 12% • $MOLN MP0712 (DLL3 target) – PoA 12% • $SLDB SGT-501 (gene therapy for CPVT) – PoA 30% Early-stage catalysts worth tracking for potential moves! Get full details & real-time updates at biopharmawatch.com #Biotech #INDFilings #Catalysts #BiotechInvesting
0 · Reply
QuiverQuant
QuiverQuant Jun. 13 at 2:57 PM
GT Biopharma, Inc. Appoints David C. Mun-Gavin to Board of Directors Read more on $GTBP: https://www.quiverquant.com/news/GT+Biopharma%2C+Inc.+Appoints+David+C.+Mun-Gavin+to+Board+of+Directors
0 · Reply
Beastmade
Beastmade Jun. 11 at 3:48 PM
$GTBP What in the MK ultra am I making money on?
1 · Reply
Beastmade
Beastmade Jun. 11 at 12:04 AM
$GTBP Shoutout to truth social for putting me on this.
0 · Reply
PhishTourFunds
PhishTourFunds Jun. 9 at 9:24 PM
$GTBP Steady as she goes
1 · Reply
kshonstocks
kshonstocks Jun. 9 at 5:33 PM
$GTBP hitting scans, higher highs
0 · Reply
nassermahashir
nassermahashir May. 28 at 10:20 AM
$GTBP wild runner will be here 🤑🤑🤑
0 · Reply
PhishTourFunds
PhishTourFunds May. 25 at 3:36 AM
$GTBP Just filling the wick on the 3 month chart to $3.12
0 · Reply
PenkeTrading
PenkeTrading May. 22 at 2:49 AM
I found you a MACD Bearish Reversal Divergence on the daily chart of GT Biopharma Inc. $GTBP #BearishReversalDivergence #NASDAQ
0 · Reply
woolpourpis69
woolpourpis69 May. 21 at 11:31 PM
$GTBP
0 · Reply
_www_larval_com_
_www_larval_com_ May. 21 at 7:57 PM
$EDBL 7%[45%] $OMH 7%[-5%] $GCL 5%[28%] $NRXP 4%[-5%] $GTBP -4%[20%] most notable movement into the final minutes of trading.
0 · Reply
PhishTourFunds
PhishTourFunds May. 21 at 6:15 PM
$GTBP Dip
0 · Reply
bilocelhi
bilocelhi May. 21 at 6:05 PM
$GTBP $4.50 PT
0 · Reply
zulutrix
zulutrix May. 21 at 5:48 PM
$GTBP whats the news
0 · Reply
BETHETHUNDER
BETHETHUNDER May. 21 at 3:16 PM
$GTBP
0 · Reply
HiPpYcHoP
HiPpYcHoP May. 21 at 3:10 PM
$GTBP LeT’s Go
0 · Reply
JediGreen
JediGreen May. 20 at 6:50 AM
$GTBP
0 · Reply
JediGreen
JediGreen May. 20 at 5:52 AM
$GTBP GTBP Dark Pool Statistics | ChartExchange https://chartexchange.com/symbol/nasdaq-gtbp/exchange-volume/
0 · Reply
JediGreen
JediGreen May. 19 at 11:13 PM
$GTBP GTBP Short Volume | ChartExchange https://chartexchange.com/symbol/nasdaq-gtbp/short-volume/
0 · Reply
sabih
sabih May. 19 at 8:14 PM
$GTBP why this is down ?
0 · Reply
MadMaverick
MadMaverick May. 19 at 6:47 PM
$GTBP Today's New: 🧠 Bottom Line: This update confirms that GTB-3650 is on the right track — safe, biologically active, and advancing through its trial. For a micro-cap biotech like GTBP, each successful phase 1 cohort materially increases its credibility, optionality, and valuation potential.
0 · Reply
Stockgurl101
Stockgurl101 May. 19 at 6:33 PM
$GTBP
0 · Reply